Knuckle pads

M13_KNUCKLEPADS

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519870
1. Apply sex-specific rule None	519870
2. Check conditions None	519870
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — M72.1 Cause of death: ICD-10 — M72.1 2 out of 7 registries used, show all original rules.	63
4. Check minimum number of events None	63
5. Include endpoints None	63
6. Filter based on genotype QC (FinnGen only)	57

Control definitions (FinnGen only)

Control exclude: M13_SOFTTISSUE

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: M72

NAME	M13_KNUCKLEPADS
CONTROL_EXCLUDE	M13_SOFTTISSUE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	M721
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	M721
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Knuckle pads based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	435	219	216
Only index persons	400	203	197
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	-	54.15	51.83
Only index persons	52.14	53.44	50.80

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	57	28	29
Unadjusted period prevalence (%)	0.01	0.01	0.01
Median age at first event (years)	56.06	52.96	59.06

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
63: Matched controls
630

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

M72.1

ICD-10 Finland

Knuckle pads

+∞

90.4

NDM10

NOMESCO Finland

Palmar fasciotomy of hand

+∞

12.9

M75.1

ICD-10 Finland

Rotator cuff syndrome

6.9

12.0

N02AX02

ATC

tramadol; systemic, rectal

5.0

8.9

171

N03AX16

ATC

[U] pregabalin

5.3

8.4

M54.5

ICD-10 Finland

Low back pain

4.4

8.0

125

R10.4

ICD-10 Finland

Other and unspecified abdominal pain

4.1

7.1

140

N02AE01

ATC

buprenorphine; parenteral, sublingual, transdermal

5.3

7.1

M72.0

ICD-10 Finland

Palmar fascial fibromatosis [Dupuytren]

25.8

6.9

TimeCodeWAS

↥

TODO / Current known limitations:

Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
Legend / how to read the glyphs.
Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
Download CSV.
No filters and sorters.
Limited amount of endpoints (~400) having TimeCodeWAS data.
Cross-links to Risteys lab test pages for lab test codes.

OMOP concept

ln(OR)

%cases with code / %controls with code

2×2 table

General Surgery
2 [38004447]

8.5e-01

1.9e+00

—

1.0e+50

2.4e+00

1.8e+00

1.3e+00

cases:34.92%

controls:18.73%

cases:26.98%

controls:5.24%

—

cases:41.27%

controls:0.00%

cases:9.52%

controls:0.96%

cases:31.15%

controls:6.74%

cases:43.10%

controls:17.58%

118

512

597

—

630

620

567

464

Outpatient Visit
OP [9202]

6.7e-01

1.4e+00

1.2e+00

—

1.8e+00

8.9e-01

cases:65.08%

controls:48.73%

cases:61.90%

controls:28.10%

cases:23.81%

controls:8.41%

—

cases:25.40%

controls:5.43%

cases:73.77%

controls:32.40%

cases:81.03%

controls:63.77%

307

323

177

453

577

—

592

197

411

359

204

Orthopedic Surgery
20 [38004465]

1.0e+00

1.9e+00

—

1.0e+50

—

2.6e+00

1.6e+00

cases:14.29%

controls:5.71%

cases:14.29%

controls:2.54%

—

cases:19.05%

controls:0.00%

—

cases:22.95%

controls:2.14%

cases:34.48%

controls:9.24%

594

614

—

630

—

595

511

diclofenac; oral, parenteral, rectal
M01AB05 [21603945]

1.2e+00

1.7e+00

—

1.6e+00

1.0e+00

cases:31.75%

controls:11.90%

cases:20.63%

controls:4.44%

—

cases:14.75%

controls:3.45%

cases:32.76%

controls:14.74%

555

602

—

587

480

Emergency Room Visit
ER [9203]

5.7e-01

8.3e-01

2.7e+00

1.0e+50

1.4e+00

1.2e+00

1.5e+00

cases:34.92%

controls:23.33%

cases:17.46%

controls:8.41%

cases:11.11%

controls:0.79%

cases:11.11%

controls:0.00%

cases:7.94%

controls:2.08%

cases:26.23%

controls:9.38%

cases:67.24%

controls:31.44%

147

483

577

625

630

613

551

177

386

temazepam; oral
N05CD07 [21604642]

1.8e+00

2.4e+00

—

2.6e+00

—

cases:11.11%

controls:2.06%

cases:9.52%

controls:0.95%

—

cases:9.84%

controls:0.82%

—

617

624

—

603

—

etoricoxib; oral
M01AH05 [21603996]

1.4e+00

1.7e+00

—

1.3e+00

cases:19.05%

controls:5.40%

cases:12.70%

controls:2.70%

—

cases:22.41%

controls:7.10%

596

613

—

523

Inpatient Hospital
21 [8717]

1.0e+00

1.1e+00

—

1.5e+00

1.4e+00

cases:50.79%

controls:27.62%

cases:22.22%

controls:9.05%

—

cases:32.79%

controls:10.20%

cases:63.79%

controls:31.08%

174

456

573

—

546

175

388

cefalexin; oral
J01DB01 [21602870]

8.7e-01

1.8e+00

2.0e+00

—

1.5e+00

7.9e-01

cases:38.10%

controls:20.48%

cases:25.40%

controls:5.40%

cases:9.52%

controls:1.43%

—

cases:26.23%

controls:7.24%

cases:43.10%

controls:25.58%

129

501

596

621

—

564

144

419

Pharmacy visit
OMOP4822462 [581458]

1.2e+00

9.1e-01

2.1e+00

8.4e-01

8.0e-01

3.2e-02

cases:96.83%

controls:90.00%

cases:90.48%

controls:74.76%

cases:58.73%

controls:36.35%

cases:12.70%

controls:1.75%

cases:55.56%

controls:34.98%

cases:88.52%

controls:77.63%

cases:93.10%

controls:92.90%

567

471

159

229

401

619

219

407

472

136

523

Outpatient Hospital
22 [8756]

8.1e-01

1.1e+00

—

1.4e+00

1.5e+00

cases:36.51%

controls:20.32%

cases:17.46%

controls:6.83%

—

cases:21.31%

controls:6.41%

cases:56.90%

controls:22.38%

128

502

587

—

569

126

437

tramadol; oral, parenteral, rectal
N02AX02 [21604298]

1.5e+00

—

1.7e+00

1.3e+00

cases:19.05%

controls:4.92%

—

cases:11.48%

controls:2.30%

cases:22.41%

controls:7.46%

599

—

594

521

Office Visit
OMOP4822458 [581477]

1.4e+00

—

1.3e+00

cases:15.87%

controls:4.29%

—

cases:29.31%

controls:10.48%

603

—

504

ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]

6.8e-01

1.4e+00

—

2.2e+00

1.2e+00

7.3e-01

cases:36.51%

controls:22.54%

cases:30.16%

controls:9.37%

—

cases:7.94%

controls:0.96%

cases:27.87%

controls:10.86%

cases:50.00%

controls:32.50%

142

488

571

—

620

542

183

380

ibuprofen
R02AX02 [1588667]

6.8e-01

1.4e+00

—

2.2e+00

1.2e+00

7.3e-01

cases:36.51%

controls:22.54%

cases:30.16%

controls:9.37%

—

cases:7.94%

controls:0.96%

cases:27.87%

controls:10.86%

cases:50.00%

controls:32.50%

142

488

571

—

620

542

183

380

Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]

—

2.4e+00

—

cases:15.52%

controls:1.60%

—

554

Treatment plan or consultation
WZC00 [2001310885]

—

2.4e+00

—

cases:10.34%

controls:1.07%

—

557

pregabalin; oral
N02BF02 [955152]

—

2.2e+00

—

cases:15.52%

controls:1.95%

—

552

Internal Medicine
11 [38004456]

1.0e+00

4.6e-01

—

1.4e+00

8.8e-01

1.1e+00

cases:36.51%

controls:17.30%

cases:11.11%

controls:7.30%

—

cases:7.94%

controls:2.08%

cases:19.67%

controls:9.21%

cases:43.10%

controls:20.60%

109

521

584

—

613

552

116

447

nimesulide; oral
M01AX17 [21604007]

2.0e+00

—

cases:11.11%

controls:1.59%

—

620

—

Other primary gonarthrosis
M17.1 [45596493]

—

2.0e+00

—

cases:13.79%

controls:2.13%

—

551

enoxaparin; parenteral
B01AB05 [21600976]

—

1.8e+00

—

cases:12.07%

controls:2.13%

—

551

Psychiatry
26 [38004469]

1.7e+00

—

1.5e+00

cases:14.29%

controls:3.02%

—

cases:13.79%

controls:3.55%

611

—

543

Thorax X-ray examination
GD1AA [2001303617]

1.5e+00

—

1.6e+00

cases:9.52%

controls:2.38%

—

cases:17.24%

controls:3.91%

615

—

541

pantoprazole; oral, parenteral
A02BC02 [21600097]

5.3e-01

1.3e+00

—

1.5e+00

1.1e+00

cases:11.11%

controls:6.83%

cases:12.70%

controls:3.97%

—

cases:14.75%

controls:3.62%

cases:24.14%

controls:9.41%

587

605

—

586

510

tizanidine; oral
M03BX02 [21604116]

1.2e+00

1.3e+00

—

1.4e+00

9.3e-01

cases:26.98%

controls:9.84%

cases:9.52%

controls:2.86%

—

cases:8.20%

controls:2.14%

cases:25.86%

controls:12.08%

568

612

—

595

495

salbutamol; inhalant
R03AC02 [21603256]

8.7e-01

7.1e-01

—

9.1e-01

6.0e-01

cases:14.29%

controls:6.51%

cases:9.52%

controls:4.92%

—

cases:11.48%

controls:4.93%

cases:17.24%

controls:10.30%

589

599

—

578

505

Teeth/gum symptom/complaint
D19 [2002000318]

—

-1.0e+50

—

cases:0.00%

controls:0.82%

cases:0.00%

controls:1.95%

—

603

552

Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]

-1.0e+50

—

cases:0.00%

controls:1.27%

—

622

—

Specific gravity of Urine by Test strip
5811-5 [3000330]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

hydrocortisone aceponate
D07AC16 [21602135]

—

-1.0e+50

—

-1.0e+50

6.4e-01

—

cases:0.00%

controls:2.38%

—

cases:0.00%

controls:2.96%

cases:12.07%

controls:6.75%

—

615

—

590

525

tamsulosin; oral
G04CA02 [21602669]

—

-1.0e+50

—

7.5e-01

—

cases:0.00%

controls:0.96%

—

cases:10.34%

controls:5.15%

—

620

—

534

atorvastatin; oral
C10AA05 [21601860]

2.9e-01

—

-1.0e+50

—

cases:7.94%

controls:6.03%

—

cases:0.00%

controls:1.90%

—

592

—

618

—

metronidazole; oral, rectal
P01AB01 [21604857]

9.9e-01

—

1.4e+00

cases:11.11%

controls:4.44%

—

cases:15.52%

controls:4.26%

602

—

539

finasteride; oral
D11AX10 [21602350]

-1.0e+50

—

1.5e+00

cases:0.00%

controls:1.59%

cases:0.00%

controls:0.95%

—

cases:8.62%

controls:2.13%

620

624

—

551

Vaccination
SPAT1325 [2001700426]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.70%

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:0.82%

—

613

624

—

603

—

intermediate-acting sulfonamides - combinations
J01EC20 [21602948]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]

—

-1.0e+50

—

cases:0.00%

controls:1.60%

—

554

Low back symptom/complaint
L03 [2002000628]

—

-1.0e+50

—

cases:0.00%

controls:1.60%

—

554

Photography of fundus of eye
XCK10 [2001301381]

-1.0e+50

—

cases:0.00%

controls:1.43%

—

621

—

beclometasone; nasal
R01AD01 [21605043]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.24%

—

624

—

556

Hemoglobin [Mass/volume] in Blood
718-7 [3000963]

-1.8e-02

5.7e-01

—

2.0e-01

-3.0e-01

cases:9.52%

controls:9.68%

cases:12.70%

controls:7.62%

—

cases:9.84%

controls:8.22%

cases:13.79%

controls:17.76%

569

582

—

558

100

463

Ophthalmology
18 [38004463]

3.1e-01

—

6.5e-01

1.8e-01

cases:9.52%

controls:7.14%

—

cases:8.20%

controls:4.44%

cases:15.52%

controls:13.32%

585

—

581

488

Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]

-1.0e+50

—

cases:0.00%

controls:1.59%

—

620

—

zopiclone; oral
N05CF01 [21604654]

7.5e-01

—

8.3e-01

cases:11.11%

controls:5.56%

—

cases:17.24%

controls:8.35%

595

—

516

Base excess in Venous blood by calculation
1927-3 [3002032]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

orphenadrine (chloride); oral, parenteral
N04AB02 [21604458]

1.4e+00

—

9.9e-01

cases:12.70%

controls:3.49%

—

cases:10.34%

controls:4.09%

608

—

540

orphenadrine, combinations
M03BC51 [21604113]

1.3e+00

—

cases:9.52%

controls:2.70%

—

613

—

telmisartan; oral
C09CA07 [21601830]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.43%

—

cases:0.00%

controls:1.64%

—

621

—

598

—

Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]

—

-1.0e+50

—

cases:0.00%

controls:2.31%

—

550

Restricted health certificate
SPAT1283 [2001700384]

—

-1.0e+50

—

cases:0.00%

controls:1.24%

—

556

Emergency visit or other similar visit involving procedures
WYA05 [2001310871]

—

1.0e+00

—

cases:13.79%

controls:5.33%

—

533

No procedures
SPAT1301 [2001700402]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.75%

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:3.73%

619

624

—

542

Knuckle pads
M72.1 [45562824]

—

1.0e+50

—

1.0e+50

—

cases:100.00%

controls:0.00%

—

cases:8.20%

controls:0.00%

—

630

—

608

—

betamethasone
A07EA04 [21600656]

6.9e-01

—

cases:7.94%

controls:4.13%

—

604

—

12 lead EKG panel
34534-8 [3044889]

—

-1.0e+50

—

cases:0.00%

controls:2.63%

—

592

—

Dorsalgia
M54 [45553203]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

dextromethorphan, combinations; oral
N07XX59 [43534835]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

Lump/swelling localized
S04 [2002000969]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

INR in Blood by Coagulation assay
34714-6 [3032080]

—

7.1e-01

—

cases:8.62%

controls:4.44%

—

538

Opening and preparing the root canals, complicated
SGA03 [2001310381]

—

-1.0e+50

—

cases:0.00%

controls:1.24%

—

556

Other and unspecified ovarian cysts
N83.2 [45539066]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]

1.4e+00

—

9.9e-01

cases:12.70%

controls:3.49%

—

cases:10.34%

controls:4.09%

608

—

540

levocabastine
S01GX02 [21605086]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]

-1.0e+50

—

cases:0.00%

controls:1.11%

cases:0.00%

controls:0.95%

—

623

624

—

pivmecillinam; oral
J01CA08 [21602827]

1.4e+00

—

7.3e-01

cases:12.70%

controls:3.33%

—

cases:12.07%

controls:6.22%

609

—

528

Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]

—

-1.0e+50

—

cases:0.00%

controls:1.42%

—

555

betamethasone
S02BA07 [21605169]

6.9e-01

—

cases:7.94%

controls:4.13%

—

604

—

codeine and paracetamol
N02AJ06 [1123647]

1.3e+00

—

9.8e-01

cases:14.29%

controls:4.29%

—

cases:22.41%

controls:9.77%

603

—

508

acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.11%

—

cases:0.00%

controls:1.15%

cases:0.00%

controls:0.89%

623

—

601

558

Plugged feeling ear
H13 [2002000480]

—

-1.0e+50

—

cases:0.00%

controls:0.99%

—

602

—

Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

betamethasone
D07AC01 [21602120]

6.9e-01

—

cases:7.94%

controls:4.13%

—

604

—

Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]

—

-1.0e+50

—

cases:0.00%

controls:3.55%

—

543

hydrocortisone
D07XA01 [21602180]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.48%

cases:0.00%

controls:2.49%

—

625

—

599

549

Ankle symptom/complaint
L16 [2002000640]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

macrogol; oral
A06AD15 [21600575]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

atenolol; oral, parenteral
C07AB03 [21601685]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.27%

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.89%

622

625

—

558

Memory test
SPAT1053 [2001700154]

—

-1.0e+50

—

cases:0.00%

controls:1.24%

—

556

X-ray examination of the lungs in one projection
GD1PA [2001303645]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Observation for other suspected diseases and conditions
Z03.89 [2000503757]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

other preparations, combinations; ointment
C05AX03 [21601631]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.22%

—

cases:0.00%

controls:0.82%

—

616

—

603

—

azelastine; nasal
R01AC03 [21605035]

-1.0e+50

—

cases:0.00%

controls:0.79%

cases:0.00%

controls:1.11%

—

625

623

—

antibiotics in combination with other drugs
S01AA20 [21603571]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

phenoxymethylpenicillin; oral
J01CE02 [21602842]

6.8e-01

—

-1.0e+50

—

6.2e-01

cases:19.05%

controls:10.63%

—

cases:0.00%

controls:0.95%

—

cases:22.41%

controls:13.50%

563

—

624

—

487

Atrial fibrillation and flutter
I48 [45596206]

1.6e+00

—

2.0e+00

—

cases:7.94%

controls:1.75%

—

cases:8.20%

controls:1.15%

—

619

—

601

—

Treatment-related counselling outside office
SPAT1249 [2001700350]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:2.06%

—

cases:0.00%

controls:0.99%

—

617

—

602

—

sitagliptin; oral
A10BH01 [21600784]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.11%

—

cases:0.00%

controls:1.42%

—

623

—

555

losartan; oral
C09CA01 [21601824]

—

1.8e+00

—

1.2e+00

—

cases:9.52%

controls:1.75%

—

cases:8.62%

controls:2.84%

—

619

—

547

chlorphenamine, combinations
R06AB54 [21603468]

1.1e+00

-1.0e+50

—

cases:11.11%

controls:3.81%

cases:0.00%

controls:0.95%

—

606

624

—

Cardiology
6 [38004451]

1.0e+00

1.9e+00

—

1.4e+00

1.1e+00

cases:11.11%

controls:4.29%

cases:7.94%

controls:1.27%

—

cases:8.20%

controls:2.14%

cases:15.52%

controls:5.68%

603

622

—

595

531

salbutamol; oral, parenteral
R03CC02 [21603312]

1.4e+00

-1.0e+50

—

cases:14.29%

controls:3.81%

cases:0.00%

controls:0.79%

—

606

625

—

General Practice
1 [38004446]

1.1e-01

—

1.1e+00

cases:7.94%

controls:7.14%

—

cases:25.86%

controls:10.66%

585

—

503

piroxicam; oral, parenteral, rectal
M01AC01 [21603961]

7.2e-01

—

cases:11.11%

controls:5.71%

—

594

—

chlorhexidine
D09AA12 [21602275]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.48%

cases:0.00%

controls:2.49%

—

625

—

599

549

ECG with 12 standard connections
XF400 [2001303368]

1.7e+00

—

cases:7.94%

controls:1.59%

—

620

—

SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: Unspecified
SMOKING-2-3-0 [2002330113]

—

-1.0e+50

—

cases:0.00%

controls:1.43%

—

621

—

Extensive MRI examination of brain with high intensity magnet
AA1CG [2001300116]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

salmeterol and fluticasone
R03AK06 [21603280]

—

-1.0e+50

—

cases:0.00%

controls:1.27%

—

622

—

Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Pneumonia, unspecified
J18.9 [45601123]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:0.82%

—

624

—

603

—

hydrocortisone; oral, parenteral
H02AB09 [21602737]

—

-1.0e+50

—

cases:0.00%

controls:1.32%

cases:0.00%

controls:1.95%

—

600

552

buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

fluticasone, combinations
R01AD58 [43534837]

-1.0e+50

—

cases:0.00%

controls:0.79%

cases:0.00%

controls:1.11%

—

625

623

—

methylprednisolone; oral, parenteral
H02AB04 [21602732]

—

-1.0e+50

—

cases:0.00%

controls:2.13%

—

551

warfarin; oral, parenteral
B01AA03 [21600965]

1.2e+00

—

cases:7.94%

controls:2.54%

—

614

—

Two-surface restoration
SFA20 [2001310359]

8.5e-01

—

1.2e+00

cases:9.52%

controls:4.29%

—

cases:22.41%

controls:8.35%

603

—

516

perindopril; oral
C09AA04 [21601788]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.89%

624

625

—

558

Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]

-1.0e+50

—

cases:0.00%

controls:1.90%

—

618

—

pH of Serum or Plasma
2753-2 [3018418]

—

-1.0e+50

—

cases:0.00%

controls:2.66%

—

548

imidazoles/triazoles in combination with corticosteroids
D01AC20 [21601936]

-1.0e+50

—

cases:0.00%

controls:4.13%

—

604

—

Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]

—

-1.0e+50

—

cases:0.00%

controls:3.55%

—

543

Disorder of lipoprotein metabolism, unspecified
E78.9 [45581384]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.07%

624

—

557

clobetasol
D07AD01 [21602141]

-1.0e+50

—

cases:0.00%

controls:1.75%

—

619

—

tiaprofenic acid; oral, rectal
M01AE11 [21603977]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Bacteria identified in Blood by Culture
600-7 [3023368]

—

-1.0e+50

—

cases:0.00%

controls:0.99%

—

602

—

fluconazole; oral, parenteral
J02AC01 [21603080]

6.8e-01

—

4.5e-01

cases:9.52%

controls:5.08%

—

cases:8.62%

controls:5.68%

598

—

531

Dental X-ray, bite-wing X-ray on one side of the mouth
EB1SA [2001301918]

—

8.4e-01

—

cases:8.62%

controls:3.91%

—

541

cromoglicic acid
S01GX01 [21605085]

—

-1.0e+50

—

cases:0.00%

controls:1.78%

—

553

diazepam; oral, parenteral, rectal
N05BA01 [21604566]

—

1.8e+00

—

cases:10.34%

controls:1.78%

—

553

phenylephrine, combinations
R01BA53 [21603214]

1.1e+00

-1.0e+50

—

cases:11.11%

controls:3.81%

cases:0.00%

controls:0.95%

—

606

624

—

Hyperplasia of prostate
N40 [45563015]

—

-1.0e+50

—

cases:0.00%

controls:1.43%

—

621

—

digoxin; oral, parenteral
C01AA05 [21600234]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Medication, disinfection of root canals
SGC00 [2001310392]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Intraoral radiographic dental examination
EB1AA [2001301903]

—

9.5e-01

—

cases:17.24%

controls:7.46%

—

521

pH of Urine by Test strip
5803-2 [3022621]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

valproic acid; oral, parenteral, rectal
N03AG01 [21604422]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

Prothrombin time (PT) actual/Normal
5894-1 [3033658]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:2.31%

624

—

550

nedocromil; inhalant
R03BC03 [21603299]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]

3.5e-01

—

-3.6e-01

cases:7.94%

controls:5.71%

—

cases:8.62%

controls:11.90%

594

—

496

chlorhexidine
S02AA09 [21605155]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.48%

cases:0.00%

controls:2.49%

—

625

—

599

549

Essential (primary) hypertension
I10 [45591453]

1.0e-01

—

-1.0e+50

9.3e-01

5.5e-01

cases:11.11%

controls:10.16%

—

cases:0.00%

controls:0.80%

cases:13.11%

controls:5.59%

cases:24.14%

controls:15.45%

566

—

621

574

476

Biopsy of endometrium
LCA06 [2001306551]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Dental examination
Z01.2 [45581002]

—

-1.0e+50

—

1.7e+00

—

cases:0.00%

controls:0.95%

—

cases:10.34%

controls:2.13%

—

624

—

551

glucosamine; oral
M01AX05 [21604002]

—

1.1e+00

—

cases:8.62%

controls:3.02%

—

546

Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]

6.5e-01

—

cases:7.94%

controls:4.29%

—

603

—

cough suppressants and expectorants
R05FB02 [21603442]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

Specific gravity of Urine by Refractometry
5810-7 [3019150]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.27%

—

cases:0.00%

controls:2.84%

622

—

547

Cerebral infarction due to thrombosis of cerebral arteries
I63.3 [45562366]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

benzathine phenoxymethylpenicillin; oral
J01CE10 [21602850]

6.8e-01

—

-1.0e+50

—

6.2e-01

cases:19.05%

controls:10.63%

—

cases:0.00%

controls:0.95%

—

cases:22.41%

controls:13.50%

563

—

624

—

487

Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]

-1.0e+50

—

cases:0.00%

controls:1.75%

—

619

—

Otolaryngology
4 [38004449]

3.9e-01

—

7.1e-01

cases:9.52%

controls:6.67%

—

cases:13.79%

controls:7.28%

588

—

522

Type 2 diabetes mellitus, without complications
E11.9 [45561952]

—

-1.0e+50

—

1.3e+00

—

cases:0.00%

controls:1.75%

—

cases:12.07%

controls:3.55%

—

619

—

543

fexofenadine; oral
R06AX26 [21603525]

-1.0e+50

—

cases:0.00%

controls:1.27%

—

622

—

pH of Venous blood
2746-6 [3012544]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

acetylsalicylic acid; oral
B01AC06 [21600991]

—

-1.0e+50

—

cases:0.00%

controls:1.15%

—

601

—

chlorhexidine
S03AA04 [21605193]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.48%

cases:0.00%

controls:2.49%

—

625

—

599

549

Diabetes, insulin-treated
103 [2001600103]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Thorax X-ray examination outside radiological department
GD1UA [2001303652]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.42%

624

—

555

Chronic atrophic gastritis
K29.4 [45567297]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

codeine; oral
R05DA04 [21603399]

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

EKG study
11524-6 [3013512]

—

-1.0e+50

—

1.2e+00

—

cases:0.00%

controls:1.11%

—

cases:8.62%

controls:2.84%

—

623

—

547

miconazole
S02AA13 [21605159]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

More than one and less than three hours
ZXE10 [2001311401]

—

1.4e+00

—

cases:13.79%

controls:3.91%

—

541

Malaise and fatigue
R53 [45553741]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Prick test
37968009 [4242723]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

Deposits [accretions] on teeth betel
K03.65 [2000502690]

-1.0e+50

—

cases:0.00%

controls:1.11%

—

623

—

salmeterol; inhalant
R03AC12 [21603266]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Cough
R05 [2002000886]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

acetylcysteine; inhalant, oral
R05CB01 [21603380]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

brompheniramine, combinations
R06AB51 [21603466]

1.1e+00

-1.0e+50

—

cases:11.11%

controls:3.81%

cases:0.00%

controls:0.95%

—

606

624

—

Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]

—

5.2e-01

—

cases:10.34%

controls:6.39%

—

527

long-acting sulfonamides - combinations
J01ED20 [21602959]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

Exposure to unspecified factor
X59 [45756412]

-1.0e+50

—

1.8e+00

cases:0.00%

controls:0.95%

—

cases:8.62%

controls:1.60%

624

—

554

Hypertension uncomplicated
K86 [2002000613]

-1.0e+50

—

cases:0.00%

controls:1.11%

—

623

—

Fall on same level involving ice and snow
W00 [45756242]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

Pure hypercholesterolaemia
E78.0 [45542771]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.11%

—

cases:0.00%

controls:0.82%

—

623

—

603

—

Other function in accordance with SHToL (Finnish classification of nursing interventions)
SPAT1292 [2001700393]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

hydrocortisone and antiseptics
D07BA04 [21602146]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.48%

cases:0.00%

controls:2.49%

—

625

—

599

549

Periodontal treatment by dental hygienist
SDE02 [2001310350]

-1.0e+50

—

cases:0.00%

controls:1.27%

cases:0.00%

controls:0.79%

—

622

625

—

One hour or less
ZXE00 [2001311394]

—

1.1e+00

—

cases:12.07%

controls:4.44%

—

538

dexamethasone and antiinfectives
S03CA01 [21605206]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

cough suppressants and mucolytics
R05FB01 [21603441]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

Emergency Room and Inpatient Visit
ERIP [262]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Dizziness and giddiness
R42 [45568132]

-1.0e+50

—

cases:0.00%

controls:1.90%

—

618

—

clindamycin; oral, parenteral
J01FF01 [21602985]

2.0e+00

—

2.2e+00

7.9e-01

cases:7.94%

controls:1.11%

—

cases:8.20%

controls:0.99%

cases:8.62%

controls:4.09%

623

—

602

540

bisoprolol and thiazides
C07BB07 [21601714]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.99%

cases:0.00%

controls:1.07%

624

625

—

602

557

Medical doctor
Z2221 [2001311556]

—

1.3e+00

—

cases:12.07%

controls:3.55%

—

543

Exposure to other specified factors
X58 [45756411]

-1.0e+50

—

2.3e+00

cases:0.00%

controls:0.95%

—

cases:8.62%

controls:0.89%

624

—

558

Laceration/cut
S18 [2002000983]

—

-1.0e+50

—

1.1e+00

—

cases:0.00%

controls:1.43%

—

cases:12.07%

controls:4.26%

—

621

—

539

Extensive angiography of hear and/or coronary arteries
FN1BC [2001303000]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Gynaecological examination (general)(routine)
Z01.4 [45542395]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.11%

—

cases:0.00%

controls:1.07%

623

—

557

pseudoephedrine, combinations; oral
R01BA52 [21603213]

6.4e-01

-1.0e+50

—

8.8e-01

cases:14.29%

controls:8.10%

cases:0.00%

controls:3.02%

—

cases:13.79%

controls:6.22%

579

611

—

528

Personal history of diseases of the digestive system
Z87.1 [45542474]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Pure hypercholesterolaemia
E78.01 [2000501514]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.15%

—

624

—

601

—

Rotator cuff syndrome
M75.1 [45596678]

—

1.0e+50

—

cases:8.20%

controls:0.00%

—

608

—

MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]

—

-3.3e-01

—

cases:10.34%

controls:13.85%

—

485

Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]

5.8e-01

4.8e-01

—

-5.4e-02

cases:7.94%

controls:4.60%

cases:7.94%

controls:5.08%

—

cases:8.62%

controls:9.06%

601

598

—

512

Counselling related to known health issue
SPAT1310 [2001700411]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.90%

—

cases:0.00%

controls:3.37%

618

—

544

Asthma, unspecified
J45.9 [45562456]

-1.0e+50

—

cases:0.00%

controls:1.75%

—

619

—

ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]

9.6e-01

—

cases:17.46%

controls:7.46%

—

583

—

clarithromycin; oral, parenteral
J01FA09 [21602977]

1.2e+00

—

cases:11.11%

controls:3.49%

—

608

—

Emergency Medicine
93 [38004510]

1.1e+00

—

7.0e-01

cases:9.52%

controls:3.49%

—

cases:12.07%

controls:6.39%

608

—

527

lisinopril; oral
C09AA03 [21601787]

-1.0e+50

—

cases:0.00%

controls:0.79%

cases:0.00%

controls:0.95%

—

625

624

—

Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
Y83 [45552036]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Basocellular carcinoma of the skin on another or unspecified part of the face
C44.31 [2000500792]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

piroxicam; ointment
M02AA07 [21604043]

9.1e-01

—

cases:11.11%

controls:4.76%

—

600

—

chloramphenicol
S01AA01 [21603554]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.43%

—

cases:0.00%

controls:0.99%

—

621

—

602

—

Skin symptom/complaint other
S29 [2002000993]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.27%

—

cases:0.00%

controls:0.89%

622

—

558

sildenafil; oral
G04BE03 [21602648]

-1.0e+50

—

cases:0.00%

controls:1.11%

cases:0.00%

controls:0.95%

—

623

624

—

Adenocarcinoma, NOS, of prostate gland
8140/3-C61.9 [44499685]

-1.0e+50

—

cases:0.00%

controls:1.27%

—

622

—

valdecoxib; oral
M01AH03 [21603994]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

diphenhydramine, combinations
R06AA52 [21603454]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

Hysterectomy
LCD00 [2001306584]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]

-1.0e+50

—

cases:0.00%

controls:4.13%

cases:0.00%

controls:2.22%

—

604

616

—

prednisolone; oral, parenteral
H02AB06 [21602734]

6.4e-01

9.6e-01

—

1.1e+00

cases:9.52%

controls:5.24%

cases:7.94%

controls:3.17%

—

cases:17.24%

controls:6.75%

597

610

—

525

Dyspnoea
R06.0 [45558449]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.15%

—

624

—

601

—

Supplier / Service Provider
OMOP5117446 [33004]

-8.7e-01

—

cases:11.11%

controls:23.02%

—

145

485

—

Intravenous general anesthesia
WX404 [2001310807]

-1.0e+50

—

1.8e+00

cases:0.00%

controls:0.95%

—

cases:8.62%

controls:1.60%

624

—

554

Transvaginal ultrasound examination of uterus, parametria and lower abdomen
LC2BE [2001306544]

1.6e+00

—

-1.0e+50

—

cases:7.94%

controls:1.75%

—

cases:0.00%

controls:1.15%

—

619

—

601

—

Atherosclerotic heart disease
I25.1 [45596196]

1.3e+00

-1.0e+50

—

cases:7.94%

controls:2.22%

cases:0.00%

controls:1.27%

—

616

622

—

hydroxyethylpromethazine, combinations
R06AD55 [21603490]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

hydrocortisone; local oral
A01AC03 [21600036]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.15%

cases:0.00%

controls:1.78%

—

625

—

601

553

roxithromycin; oral
J01FA06 [21602974]

3.1e-01

—

4.1e-01

cases:9.52%

controls:7.14%

—

cases:10.34%

controls:7.10%

585

—

523

Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10886-0 [3005013]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.59%

—

cases:0.00%

controls:1.32%

—

620

—

600

—

Removal of sutures
SPAT1153 [2001700254]

-1.0e+50

—

1.6e+00

cases:0.00%

controls:1.43%

—

cases:10.34%

controls:2.31%

621

—

550

insulin (beef); parenteral
A10AD02 [21600730]

-1.0e+50

—

cases:0.00%

controls:1.75%

—

619

—

Neurology
13 [38004458]

1.4e-01

—

8.1e-01

cases:7.94%

controls:6.98%

—

cases:22.41%

controls:11.37%

586

—

499

Chronic obstructive pulmonary disease with acute lower respiratory infection
J44.0 [45601131]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

Protein [Presence] in Urine by Test strip
20454-5 [3014051]

—

-1.0e+50

—

cases:0.00%

controls:2.66%

—

548

furosemide and potassium-sparing agents
C03EB01 [21601554]

-1.0e+50

—

cases:0.00%

controls:0.79%

cases:0.00%

controls:0.79%

—

625

—

Urology
34 [38004474]

—

-1.0e+50

1.0e+00

—

cases:0.00%

controls:2.47%

cases:12.07%

controls:4.80%

—

593

536

SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: Unspecified
SMOKING-1-1-0 [2002330116]

-1.0e+50

—

cases:0.00%

controls:2.22%

—

616

—

Lumbar and other intervertebral disc disorders with radiculopathy
M51.1 [45562747]

—

2.3e+00

—

cases:8.62%

controls:0.89%

—

558

metoprolol; oral, parenteral
C07AB02 [21601684]

3.2e-01

—

2.4e-01

cases:7.94%

controls:5.87%

—

cases:8.62%

controls:6.93%

593

—

524

Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.27%

—

cases:0.00%

controls:1.32%

—

622

—

600

—

CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Other medical or dental certificate
WZA90 [2001310883]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

other antifungals for topical use - combinations; ointment
D01AE20 [21601959]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.48%

cases:0.00%

controls:2.49%

—

625

—

599

549

cyproterone and estrogen
G03HB01 [21602617]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

Sleep apnoea
G47.3 [45562094]

1.6e+00

—

cases:7.94%

controls:1.75%

—

619

—

hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]

—

-1.0e+50

—

cases:0.00%

controls:0.80%

—

621

—

itraconazole; oral, parenteral
J02AC02 [21603081]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.27%

—

cases:0.00%

controls:1.07%

—

622

—

557

linagliptin; oral
A10BH05 [40251691]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

Chronic ischaemic heart disease
I25 [45581765]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

acetylcysteine
V03AB23 [21605248]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

paracetamol; oral, parenteral, rectal
N02BE01 [21604344]

7.8e-01

3.1e-01

—

1.2e+00

8.3e-01

cases:23.81%

controls:12.54%

cases:9.52%

controls:7.14%

—

cases:14.75%

controls:4.77%

cases:36.21%

controls:19.89%

551

585

—

579

112

451

Periodontitis pronounced
K05.31 [2000502729]

-1.0e+50

—

cases:0.00%

controls:0.95%

—

624

—

Glucose tolerance 2 hours panel - Serum or Plasma
72171-2 [43054914]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Thoracic and Cardiac Surgery
OMOP4822009 [45756830]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Physical Medicine And Rehabilitation
25 [38004468]

—

2.0e+00

1.6e+00

—

cases:9.84%

controls:1.48%

cases:12.07%

controls:2.66%

—

599

548

metronidazole; vaginal
G01AF01 [21602392]

—

-1.0e+50

—

cases:0.00%

controls:0.99%

—

602

—

diltiazem; oral
C08DB01 [21601771]

—

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:1.11%

—

cases:0.00%

controls:0.99%

cases:0.00%

controls:1.07%

—

623

—

602

557

oxybutynin; oral, transdermal
G04BD04 [21602637]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

hydrocortisone
A07EA02 [21600654]

—

-1.0e+50

—

-1.0e+50

6.1e-01

—

cases:0.00%

controls:2.38%

—

cases:0.00%

controls:2.96%

cases:12.07%

controls:6.93%

—

615

—

590

524

Presence of aortocoronary bypass graft
Z95.1 [45556881]

—

-1.0e+50

—

cases:0.00%

controls:0.89%

—

558

Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]

9.0e-02

2.7e-01

—

2.6e-01

-2.2e-01

cases:7.94%

controls:7.30%

cases:7.94%

controls:6.19%

—

cases:8.20%

controls:6.41%

cases:12.07%

controls:14.56%

584

591

—

569

481

Other investigative procedure of eye
XCW99 [2001301491]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.60%

625

—

554

Uroflowmetry
44856007 [4261340]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.99%

—

625

—

602

—

amlodipine; oral
C08CA01 [21601747]

—

-1.0e+50

—

1.7e-01

—

cases:0.00%

controls:1.76%

—

cases:10.34%

controls:8.88%

—

615

—

513

Sampling
SPAT1263 [2001700364]

—

-1.0e+50

7.9e-01

—

cases:0.00%

controls:0.99%

cases:8.62%

controls:4.09%

—

602

540

Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]

2.4e-01

—

cases:7.94%

controls:6.35%

—

590

—

combinations of corticosteroids
D07XB30 [21602188]

1.2e-01

1.0e+00

—

3.3e-01

cases:11.11%

controls:10.00%

cases:7.94%

controls:3.02%

—

cases:13.79%

controls:10.30%

567

611

—

505

Limited function/disability NOS
A28 [2002000162]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Root filling of tooth with one root canal
SGB10 [2001310388]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.42%

624

—

555

sertraline; oral
N06AB06 [21604714]

—

-1.0e+50

—

cases:0.00%

controls:1.60%

—

554

Fall on same level from slipping, tripping and stumbling
W01 [45756243]

—

1.0e+00

—

cases:8.62%

controls:3.20%

—

545

Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]

—

1.1e-01

—

cases:8.62%

controls:7.82%

—

519

bisoprolol; oral
C07AB07 [21601689]

7.7e-01

9.4e-01

9.6e-01

—

1.6e+00

4.2e-01

2.3e-01

cases:17.46%

controls:8.89%

cases:19.05%

controls:8.41%

cases:7.94%

controls:3.17%

—

cases:11.11%

controls:2.56%

cases:14.75%

controls:10.20%

cases:20.69%

controls:17.23%

574

577

610

—

610

546

466

Upper gastrointestinal surgery
106 [44777669]

—

6.5e-01

—

cases:10.34%

controls:5.68%

—

531

Curettage of cervix and body of uterus
LCA13 [2001306553]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Spontaneous vertex delivery
O80.0 [45577661]

—

-1.0e+50

—

cases:0.00%

controls:1.78%

—

553

Repair of inguinal hernia using prosthetic material
JAB30 [2001304393]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.60%

625

—

554

Additional procedure necessary for restorative treatment
SFC01 [2001310369]

—

2.0e+00

—

cases:10.34%

controls:1.60%

—

554

glucagon; nasal, parenteral
H04AA01 [21602778]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Laboratory Visit
OMOP4822461 [32036]

-1.6e-01

1.7e-01

1.3e+00

—

2.7e-01

-3.2e-01

cases:9.52%

controls:10.95%

cases:12.70%

controls:10.95%

cases:7.94%

controls:2.38%

—

cases:13.11%

controls:10.36%

cases:15.52%

controls:20.25%

561

615

—

545

114

449

betamethasone
C05AA05 [21601610]

6.9e-01

—

cases:7.94%

controls:4.13%

—

604

—

hydrocortisone and antiinfectives
S01CA03 [21603654]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.07%

624

—

557

dexamethasone; oral, parenteral
H02AB02 [21602730]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.82%

cases:0.00%

controls:1.42%

624

625

—

603

555

Right side
ZXA00 [2001311346]

—

1.2e+00

—

cases:8.62%

controls:2.84%

—

547

hydrocortisone and antiinfectives
S03CA04 [21605208]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.11%

—

cases:0.00%

controls:1.60%

623

—

554

Unilateral or unspecified inguinal hernia, without obstruction or gangrene
K40.9 [45543307]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.43%

—

cases:0.00%

controls:2.31%

621

—

550

Pain in joint
M25.5 [45586941]

—

-1.0e+50

—

cases:0.00%

controls:1.60%

—

554

esomeprazole; oral, parenteral
A02BC05 [21600100]

1.1e+00

1.3e+00

—

5.1e-01

cases:11.11%

controls:3.97%

cases:9.52%

controls:2.70%

—

cases:12.07%

controls:7.64%

605

613

—

520

opium derivatives and expectorants
R05FA02 [21603439]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

ketorolac
S01BC05 [21603643]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:0.89%

625

—

558

erdosteine; oral
R05CB15 [21603394]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.60%

625

—

554

insulin lispro; parenteral
A10AD04 [21600732]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:1.43%

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:0.99%

cases:0.00%

controls:1.24%

621

624

—

602

556

Hand Surgery
40 [38004480]

—

1.0e+50

—

cases:11.11%

controls:0.00%

—

630

—

Chronic obstructive pulmonary disease, unspecified
J44.9 [45548115]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Urgent procedure
ZXD05 [2001311386]

1.1e+00

—

1.4e+00

cases:7.94%

controls:2.70%

—

cases:10.34%

controls:2.84%

613

—

547

Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]

2.4e-01

5.2e-01

—

-1.0e+50

—

-2.6e-01

cases:9.52%

controls:7.62%

cases:9.52%

controls:5.87%

—

cases:0.00%

controls:1.12%

—

cases:12.07%

controls:15.10%

582

593

—

619

—

478

Caries of dentine
K02.1 [45548134]

—

-1.0e+50

—

6.7e-01

—

cases:0.00%

controls:0.79%

—

cases:12.07%

controls:6.57%

—

625

—

526

levothyroxine sodium; oral, parenteral
H03AA01 [21602754]

5.8e-01

9.3e-01

—

1.2e+00

1.1e+00

cases:7.94%

controls:4.60%

cases:9.52%

controls:3.97%

—

cases:11.48%

controls:3.78%

cases:15.52%

controls:5.86%

601

605

—

585

530

Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]

—

-1.0e+50

—

cases:0.00%

controls:1.75%

—

619

—

naproxen; oral, rectal
M01AE02 [21603968]

9.8e-01

—

3.5e-02

cases:19.05%

controls:8.10%

—

cases:8.62%

controls:8.35%

579

—

516

terbutaline; inhalant
R03AC03 [21603257]

—

-1.0e+50

—

cases:0.00%

controls:1.43%

—

621

—

lercanidipine; oral
C08CA13 [21601759]

-1.0e+50

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

cases:0.00%

controls:1.32%

—

625

—

600

—

fenoterol and ipratropium bromide
R03AL01 [43534843]

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

promethazine, combinations
R06AD52 [21603489]

1.2e+00

-1.0e+50

—

cases:11.11%

controls:3.65%

cases:0.00%

controls:0.79%

—

607

625

—

estriol
G03CC06 [21602534]

-1.0e+50

—

-1.0e+50

cases:0.00%

controls:0.95%

—

cases:0.00%

controls:1.24%

624

—

556

prednisolone
A07EA01 [21600653]

6.4e-01

9.6e-01

—

1.1e+00

cases:9.52%

controls:5.24%

cases:7.94%

controls:3.17%

—

cases:17.24%

controls:6.75%

597

610

—

525

Health maint/preventive medicine
A98 [2002000231]

-1.9e-01

5.2e-01

—

-1.0e+50

-2.5e-02

2.3e-01

cases:9.52%

controls:11.27%

cases:12.70%

controls:7.94%

—

cases:0.00%

controls:0.80%

cases:8.20%

controls:8.39%

cases:24.14%

controls:20.25%

559

580

—

621

557

114

449

Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]

—

-1.0e+50

—

cases:0.00%

controls:1.24%

—

556

norethisterone and ethinylestradiol
G03AA05 [21602478]

—

-1.0e+50

—

cases:0.00%

controls:0.79%

—

625

—

Heart failure, unspecified
I50.9 [45576879]

—

-1.0e+50

—

cases:0.00%

controls:1.07%

—

557

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3019198) Lymphocytes [#/volume] in Blood

254

2.96

4.01

5.4

6.3

1.80

1.70

e9/l

0.32

221

(3013115) Eosinophils [#/volume] in Blood

255

2.94

3.97

5.4

7.1

0.19

0.17

e9/l

0.32

214

(3006315) Basophils [#/volume] in Blood

246

2.91

3.95

5.4

6.3

0.05

0.04

e9/l

1.74

201

(42870588) Differential panel, method unspecified - Blood

170

2.79

3.87

5.1

4.5

—

(3013650) Neutrophils [#/volume] in Blood by Automated count

305

2.88

3.48

6.9

11.8

4.35

4.30

e9/l

0.04

254

(3001604) Monocytes [#/volume] in Blood

248

2.68

3.45

5.5

6.3

0.57

0.59

e9/l

0.19

205

(3004789) Transferrin [Mass/volume] in Serum or Plasma

2.93

3.39

5.1

2.4

2.41

2.34

g/l

0.22

(3018095) Leukocytes [#/volume] in Urine

222

2.45

3.00

5.7

3.5

632.26

106.99

e6/l

0.45

148

(3022250) Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction

2.86

2.92

2.5

4.6

235.94

257.79

u/l

0.41

(3024561) Albumin [Mass/volume] in Serum or Plasma

252

2.44

2.90

8.3

4.1

35.53

35.37

g/l

0.05

239

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

203

2.31

2.68

4.5

3.0

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

318

2.45

2.63

6.6

4.8

6.44

6.68

mmol/l

0.40

301

(3011288) Drugs identified in Urine by Screen method Nominal

7.63

2.59

2.6

1.1

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

2.53

2.54

4.2

3.1

4.12

3.29

e6/l

—

(3026008) Bacteria identified in Urine by Culture

165

2.25

2.48

6.4

3.3

—

(3021589) Normoblasts [#/volume] in Blood

245

2.24

2.46

10.9

11.8

0.00

e9/l

0.71

189

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

6.67

2.41

1.0

1.6

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

2.46

2.41

2.2

1.8

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

5.92

2.25

1.2

—

(3023368) Bacteria identified in Blood by Culture

154

2.17

2.23

4.0

3.9

—

(3018418) pH of Serum or Plasma

189

2.12

2.19

5.5

4.4

7.39

7.40

0.21

132

(36304419) Bacteria [Presence] in Urine

155

2.15

2.19

5.0

2.9

—

estimate

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

2.53

2.13

2.3

1.8

—

(3019060) Gas panel - Arterial blood

3.11

2.10

5.6

4.7

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

2.28

2.06

4.1

2.9

0.77

1.47

e6/l

—

(3049717) Cytology report of Urine Cyto stain

3.61

2.03

2.1

3.1

—

(3037467) Urinalysis macro (dipstick) panel - Urine

358

2.23

2.03

7.5

4.1

—

(3013707) Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method

380

2.30

2.01

4.6

4.0

13.69

12.84

mm/h

0.14

344

(3035995) Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma

416

2.43

1.94

9.9

7.4

84.52

79.19

u/l

0.36

387

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

2.36

1.87

2.3

1.6

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

3.29

1.86

2.7

2.1

—

(3046870) Tissue transglutaminase IgG Ab [Units/volume] in Serum

3.15

1.78

1.1

1.0

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

229

1.93

1.74

3.0

2.1

92.94

94.80

pmol/l

0.08

115

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

134

1.99

1.69

3.4

2.4

—

(40768797) Stomach Pathology biopsy report

2.30

1.68

1.0

1.3

—

(3005895) Myoglobin [Mass/volume] in Serum or Plasma

3.78

1.65

1.2

1.6

2035.80

232.50

ug/l

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

246

1.83

1.52

3.5

2.6

—

estimate

—

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

2.52

1.50

9.2

3.2

108.56

76.35

ng/l

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

3.30

1.46

3.4

1.5

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

107

1.96

1.46

3.3

3.4

28.72

319.86

ng/l

0.68

(3001122) Ferritin [Mass/volume] in Serum or Plasma

223

1.77

1.37

6.4

3.0

83.54

129.97

ug/l

1.75

210

(3019832) Treponema pallidum Ab [Presence] in Serum

2.27

1.37

2.3

1.5

—

(3027945) Reticulocytes/Erythrocytes in Blood

2.08

1.36

2.3

3.0

1.59

1.69

0.16

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

2.65

1.34

1.0

1.6

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

2.05

1.31

2.8

1.5

—

(40758558) Short blood count panel - Blood

162

1.78

1.31

3.9

7.5

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

284

1.73

1.28

3.3

2.9

—

(1761868) Lipid panel - Serum or Plasma

211

0.52

1.28

3.0

3.1

—

(3023081) Carboxyhemoglobin/Hemoglobin.total in Blood

2.54

1.27

3.5

4.6

1.57

1.73

—

(40768443) Skin Pathology biopsy report

2.50

1.11

1.0

—

(3000494) Fungus identified in Specimen by Culture

1.94

1.09

1.2

1.4

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

1.90

1.09

1.4

1.2

1.20

5.15

u/ml

—

(3044640) Blood type and Crossmatch panel - Blood

189

1.64

1.05

2.8

2.3

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

2.06

1.00

1.7

1.6

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

528

2.24

1.00

28.5

18.4

3.96

3.97

mmol/l

0.08

513

(3019550) Sodium [Moles/volume] in Serum or Plasma

527

2.26

1.00

28.3

18.3

139.60

139.74

mmol/l

0.15

512

(40768804) Tissue Pathology biopsy report

219

1.60

1.00

2.5

2.3

—

(3044889) 12 lead EKG panel

378

1.67

0.99

4.1

4.2

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

113

1.69

0.95

1.6

1.4

1.10

1.41

mg/l

0.23

(3017143) Hepatitis C virus Ab [Presence] in Serum

1.93

0.94

3.2

1.6

—

(3042936) Bacteria identified in Isolate by Culture

1.79

0.93

2.6

1.9

—

(3023024) Carbon dioxide [Partial pressure] in Capillary blood

2.03

0.93

4.6

3.0

5.19

5.07

kpa

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

2.03

0.87

7.7

4.9

22.43

24.24

mmol/l

—

(3030981) Hyaline casts [#/volume] in Urine by Automated count

1.76

0.82

2.5

2.2

0.43

1.96

e6/l

—

(3022145) Colonoscopy Study observation

1.83

0.81

1.2

1.3

—

(3022313) Gas panel - Capillary blood

2.08

0.74

5.2

3.4

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

1.79

0.73

1.9

1.4

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.00

0.72

1.0

1.3

—

(3004588) Protein electrophoresis panel - Serum or Plasma

1.70

0.69

1.0

4.1

—

(3035350) Ketones [Presence] in Urine by Test strip

282

1.45

0.69

4.9

4.0

135.55

0.00

estimate

0.47

(3028026) IgM [Mass/volume] in Serum or Plasma

1.85

0.67

1.2

1.7

0.98

1.08

g/l

—

(3003458) Phosphate [Moles/volume] in Serum or Plasma

1.62

0.65

16.8

4.5

1.07

1.03

mmol/l

0.19

(3007853) Bacteria identified in Skin by Aerobe culture

1.65

0.63

3.7

1.4

—

(3025941) Bacteria identified in Stool by Culture

1.72

0.63

1.0

1.3

—

(3014007) Fractional oxyhemoglobin in Arterial blood

1.84

0.60

14.7

9.6

94.23

92.19

—

(3012516) Albumin [Mass/volume] in Urine

174

1.41

0.55

5.3

3.1

44.69

56.86

mg/l

0.13

111

(3009261) Glucose [Presence] in Urine by Test strip

290

1.37

0.55

4.8

4.0

0.00

estimate

—

(3013512) EKG study

175

1.40

0.53

3.8

4.0

—

(3021601) Nitrite [Presence] in Urine by Test strip

281

1.37

0.53

4.8

4.0

0.00

estimate

—

(4010399) Spirometry for bronchospasm with prolonged evaluation after bronchodilator

1.62

0.51

1.6

1.4

—

(3000991) Gas panel - Venous blood

1.45

0.47

16.6

7.3

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

162

1.34

0.43

3.9

4.7

16.88

21.69

—

(4034850) Laboratory test

0.00

0.42

0.0

9.0

—

(3010156) C reactive protein [Mass/volume] in Serum or Plasma by High sensitivity method

0.00

0.42

0.0

2.2

—

3.59

—

(3037756) Immunofixation for Serum or Plasma

0.00

0.41

0.0

2.4

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

555

1.57

0.38

29.8

20.3

91.05

80.09

umol/l

0.53

546

(3002385) Erythrocyte [DistWidth] in Red Blood Cells

445

1.33

0.36

27.7

19.4

13.87

13.74

0.23

436

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.44

0.36

2.3

2.0

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.39

0.35

3.7

1.8

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

212

0.79

0.30

5.3

4.2

0.00

0.07

estimate

—

(3017446) Testosterone [Moles/volume] in Serum or Plasma

1.33

0.29

2.9

2.0

11.26

13.52

nmol/l

—

(40760892) CBC W Ordered Manual Differential panel - Blood

114

1.29

0.28

3.1

5.7

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

269

1.22

0.27

11.8

6.1

1.20

1.21

mmol/l

0.38

241

(3014576) Chloride [Moles/volume] in Serum or Plasma

1.21

0.26

12.2

6.0

106.00

104.51

mmol/l

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

1.30

0.24

1.5

1.6

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

1.34

0.24

2.4

1.7

—

(3003694) ABO and Rh group [Type] in Blood

155

0.80

0.23

1.9

1.4

—

(3025159) Blasts/Leukocytes in Blood

1.27

0.23

3.2

4.7

—

0.40

—

(36660697) Celiac disease serology panel - Serum

1.24

0.22

1.2

—

(3007844) Epstein Barr virus capsid IgM Ab [Units/volume] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(40769539) Bacteria identified based on 16S rRNA gene [Identifier] in Specimen by Sequencing

0.00

0.21

0.0

1.7

—

(44790049) Parainfluenza type 3 nucleic acid detection

0.00

0.21

0.0

1.7

—

(44790047) Parainfluenza type 1 nucleic acid detection

0.00

0.21

0.0

1.8

—

(44806118) Parainfluenza type 4 nucleic acid detection

0.00

0.21

0.0

1.8

—

(44790048) Parainfluenza type 2 nucleic acid detection

0.00

0.21

0.0

1.8

—

(3000492) Spirometry study

1.28

0.21

1.2

1.6

—

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.8

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

0.21

0.0

4.0

—

14.38

—

(40761536) Microorganisms panel - Urine sediment

1.25

0.21

6.3

3.0

—

(3005785) Creatine kinase.MB [Mass/volume] in Serum or Plasma

1.22

0.20

2.0

2.5

4.68

10.29

ug/l

—

(1761482) Bacteria [#/volume] in Urine by Culture

0.00

0.20

0.0

4.1

—

(3007164) IgA [Mass/volume] in Serum or Plasma

101

1.23

0.18

1.2

1.6

2.34

2.58

g/l

—

(3015736) pH of Urine

219

1.15

0.16

4.8

3.9

6.12

6.27

0.19

114

(3002256) Pathology report gross observation

1.13

0.16

1.6

1.4

—

(3020682) Albumin/Creatinine [Ratio] in Urine

180

1.16

0.15

6.0

3.9

8.21

9.43

mg/mmol

0.06

112

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

212

1.13

0.12

4.1

5.2

1.87

1.86

ug/l

0.01

185

(3041096) Erythrocytes [Presence] in Urine by Automated

156

0.87

0.11

5.8

3.2

0.00

estimate

—

(3029937) Albumin [Presence] in Urine by Test strip

155

1.13

0.10

5.0

4.5

0.00

0.03

estimate

—

(3048816) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood

1.12

0.09

1.0

4.3

1.25

1.23

mmol/l

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

117

1.14

0.09

2.6

1.9

464.23

118182219.62

pmol/l

0.50

(40761511) CBC panel - Blood by Automated count

539

1.16

0.07

17.6

13.8

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

208

1.09

0.06

3.2

4.3

43.60

40.30

ng/l

0.05

155

(3019150) Specific gravity of Urine by Refractometry

114

1.07

0.01

4.4

5.0

1.01

1.02

kg/l

—

(21494434) Karyotype in Bone marrow

0.00

0.0

1.0

—

(3003434) Protein [Mass/volume] in Pleural fluid

0.00

0.0

2.0

—

33.80

—

(3000924) Streptococcus pyogenes [Presence] in Throat by Organism specific culture

0.00

0.0

1.5

—

(4268621) Lupus anticoagulant assay

0.00

0.0

2.5

—

(3044941) Cell count panel - Synovial fluid

0.00

0.0

1.5

—

(3036428) Adenosine deaminase [Enzymatic activity/volume] in Pleural fluid

0.00

0.0

1.3

—

7.33

—

(3007821) Glucose [Moles/volume] in Serum or Plasma --baseline

0.00

0.0

1.3

—

9.63

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

0.88

-0.00

4.3

3.5

—

(3038177) Helicobacter pylori Ab [Presence] in Serum

0.00

-0.00

0.0

1.1

—

(3041642) Human coronavirus 229E RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.9

—

(3051651) Icteric interference index of Serum or Plasma

0.00

-0.00

0.0

2.4

—

0.60

—

(3036782) Glucose [Moles/volume] in Pleural fluid

0.00

-0.00

0.0

1.4

—

6.46

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

0.98

-0.00

3.6

9.0

—

(40768795) Lymph node Pathology biopsy report

0.00

-0.00

0.0

1.1

—

(3045142) Bone marrow Pathology biopsy report

0.00

-0.00

0.0

1.1

—

(3022806) Fractional oxyhemoglobin in Capillary blood

0.00

-0.00

0.0

1.0

—

89.84

—

(3035285) Chloride [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.6

—

108.40

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.02

-0.00

1.3

1.4

—

(44816752) ERBB2 gene copy number/nucleus in Tissue by FISH

0.00

-0.00

0.0

1.1

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

-0.00

0.0

1.6

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

-0.00

0.0

1.3

—

62.09

—

(3044927) Protein electrophoresis panel - Urine

0.00

-0.00

0.0

1.0

—

(3012441) Differential panel - Pleural fluid

0.00

-0.00

0.0

2.0

—

(3009466) Valproate [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

2.8

—

334.20

—

(3032700) Glomerular basement membrane Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.1

—

(3018301) Testosterone Free [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

1.0

—

160.78

—

(3016914) Bacteria identified in Cerebral spinal fluid by Culture

0.00

-0.00

0.0

1.0

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(21494890) Protein electrophoresis panel - 24 hour Urine

0.00

-0.00

0.0

6.9

—

(40768806) Pleura Pathology biopsy report

0.00

-0.00

0.0

3.4

—

(3000081) cloZAPine [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

23.9

—

1663.14

—

(3033705) Calcium.ionized [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.6

—

1.16

—

(3041354) Potassium [Moles/volume] in Venous blood

0.00

-0.00

0.0

3.6

—

3.96

—

(43055361) Metamyelocytes/Leukocytes [Pure number fraction] in Blood by Manual count

0.00

-0.00

0.0

2.0

—

1.40

—

(3038546) Human coronavirus OC43 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.9

—

(3040359) Human coronavirus NL63 RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.9

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

-0.00

0.0

1.5

—

(3016881) Enterovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.8

—

(3000034) Microalbumin [Mass/volume] in Urine

0.00

-0.00

0.0

4.8

—

11.54

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

-0.00

0.0

1.4

—

(3042631) Mycobacterium sp identified in Specimen

0.00

-0.00

0.0

2.0

—

(3004451) EKG impression Narrative

0.00

-0.00

0.0

1.4

—

(3035947) Staphylolysin Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.0

—

(44806420) Estimation of glomerular filtration rate

0.00

-0.00

0.0

1.8

—

(40763082) Lactate dehydrogenase [Enzymatic activity/volume] in Pleural fluid by Lactate to pyruvate reaction

0.00

-0.00

0.0

1.6

—

201.20

—

(3025130) Human papilloma virus identified in Specimen

0.00

-0.00

0.0

2.0

—

(3025023) Rhinovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.7

—

Mortality – FinRegistry

↥

Association

Association between endpoint M13_KNUCKLEPADS and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have M13_KNUCKLEPADS.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: M13_KNUCKLEPADS – Knuckle pads

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Knuckle pads

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

TimeCodeWAS

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints